ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function
Sophie Irwin, Andrea Chupina Estrada, Becca Nelson, Ashlen Bullock, Berkeley Limketkai, Wendy Ho, Susan Acton, Laurent Chesnel, Hon Wai Koon · 2024
Read ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function by Sophie Irwin, Andrea Chupina Estrada, Becca Nelson, Ashlen Bullock, Berkeley Limketkai, Wendy Ho, Susan Acton, Laurent Chesnel, Hon Wai Koon (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10806143.txt.
Description
Sophie Irwin and co-authors test a live bacterial therapy, ADS024, against ulcerative colitis in work dated two thousand twenty-three. The gut lining in that disease loses cells and turns leaky. ADS024 is one strain of Bacillus velezensis, a microbe being readied as a drug.
A sterile brew of the strain's secretions shielded colon tissue from colitis patients and human gut cells in the lab. It cut cell death and swelling signals, and blunted death caused by patient serum particles. It also eased a plunge in barrier strength from two swelling chemicals and kept a key seal protein at normal levels. Fed to mice with colon injury, the live strain cut weight loss and tissue damage.
Catalog record
| CREATOR | Sophie Irwin, Andrea Chupina Estrada, Becca Nelson, Ashlen Bullock, Berkeley Limketkai, Wendy Ho, Susan Acton, Laurent Chesnel, Hon Wai Koon |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |